Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00280644 |
Study objectives:
Condition | Intervention | Phase |
---|---|---|
Arthritis, Rheumatoid |
Drug: Leflunomide |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study |
Official Title: | Efficacy of Leflunomide on Joint Inflammation and Destruction of Joint Integrity in Active Rheumatoid Arthritis (RA) Patients |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | HWA486/4022 |
Study First Received: | January 19, 2006 |
Last Updated: | December 10, 2007 |
ClinicalTrials.gov Identifier: | NCT00280644 History of Changes |
Health Authority: | Turkey: Ministry of Health |
Autoimmune Diseases Immunologic Factors Musculoskeletal Diseases Leflunomide Joint Diseases Arthritis |
Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases Antirheumatic Agents Immunosuppressive Agents Inflammation |
Autoimmune Diseases Immunologic Factors Immune System Diseases Molecular Mechanisms of Pharmacological Action Joint Diseases Leflunomide Physiological Effects of Drugs Arthritis, Rheumatoid Enzyme Inhibitors |
Rheumatic Diseases Immunosuppressive Agents Pharmacologic Actions Musculoskeletal Diseases Therapeutic Uses Arthritis Connective Tissue Diseases Antirheumatic Agents |